title: [Not Available].
abstract: Teicoplanin is a glycopeptid antibiotic used for treatment of serious infections caused by Gram+ bacteriae. The treatment scheme corresponds to an initial loading dose followed by maintenance dose. High interindividual pharmacokinetic variability and strong relation between high through concentrations, dose and clinical success, support the need of therapeutic drug monitoring using through concentrations. Achieving through concentrations ≥10-15 mg/L or ≥20-40 mg/L, regarding the measurement method and the infection severity, is recommended to increase clinical success rate. The level of proof of therapeutic drug monitoring is evaluated: "necessary".
authors.affiliation: Laboratoire de Pharmacologie Médicale et Clinique, CHU Marseille, Université de la Méditerranée, Marseille, France. Electronic address: audrey.boulamery@univmed.fr.
authors.forename: Audrey
authors.initials: A
authors.lastname: Boulamery
authors.affiliation: Laboratoire de Toxicologie et Pharmacocinétique, CHU Poitiers, Poitiers, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Venisse
authors.affiliation: CHRU de Tours, Université François-Rabelais, Tours, France.
authors.forename: Chantal
authors.initials: C
authors.lastname: Le Guellec
keywords: suivi thérapeutique pharmacologique; teicoplatin; teicoplatine; therapeutic drug monitoring